This Recent MMJ Study Shows Promise for Multiple Sclerosis Patients
Veriheal
APRIL 7, 2022
They stated in their report that while treatment for MS has come a long way and improved life expectancy for MS patients, the remyelination is still falling short due to neuropathologic deterioration and relapse in individuals with MS. Of the surveyed patients, only 26% reported using it for symptoms.
Let's personalize your content